BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chung RT, Baumert TF. Curing chronic hepatitis C--the arc of a medical triumph. N Engl J Med. 2014;370:1576-1578. [PMID: 24720678 DOI: 10.1056/nejmp1400986] [Cited by in Crossref: 163] [Cited by in F6Publishing: 90] [Article Influence: 20.4] [Reference Citation Analysis]
Number Citing Articles
1 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
2 Eller C, Heydmann L, Colpitts CC, Verrier ER, Schuster C, Baumert TF. The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses. Cell Mol Life Sci. 2018;75:3895-3905. [PMID: 30097692 DOI: 10.1007/s00018-018-2892-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
3 O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 2018; 24(39): 4436-4447 [PMID: 30357021 DOI: 10.3748/wjg.v24.i39.4436] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
4 Simon KA, Flisiak R, Łapiński TW, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Rostkowska KA, Piekarska A, Tronina O, Madej G, Garlicki A, Łucejko M, Pisula A, Karpińska E, Kryczka W, Wiercińska-Drapało A, Mozer-Lisewska I, Jabłkowski MS, Horban A, Knysz B, Tudrujek M, Halota W. Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study. Clin Exp Hepatol 2019;5:215-23. [PMID: 31598558 DOI: 10.5114/ceh.2019.87634] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 2015;64:483-94. [PMID: 24848265 DOI: 10.1136/gutjnl-2013-306155] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 8.4] [Reference Citation Analysis]
6 Zeisel MB, Baumert TF. Clinical development of hepatitis C virus host-targeting agents. Lancet 2017;389:674-5. [PMID: 28087068 DOI: 10.1016/S0140-6736(17)30043-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Colpitts CC, Baumert TF. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure. Viruses 2016;8:E226. [PMID: 27537906 DOI: 10.3390/v8080226] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
8 Hyrina A, Olmstead AD, Steven P, Krajden M, Tam E, Jean F. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9. EBioMedicine 2017;23:68-78. [PMID: 28864162 DOI: 10.1016/j.ebiom.2017.08.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
9 Stanciu C, Trifan A. Hepatitis C Virus Treatment Revolution: Eastern European Story. Hepat Mon. 2015;15:e28969. [PMID: 26300932 DOI: 10.5812/hepatmon.28969v2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
10 Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines 2016;15:1535-44. [PMID: 27267297 DOI: 10.1080/14760584.2016.1194759] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
11 Li W, Xiao F, Zhou M, Jiang X, Liu J, Si H, Xie M, Ma X, Duan Y, Zhai H. 3D-QSAR study and design of 4-hydroxyamino α-pyranone carboxamide analogues as potential anti-HCV agents. Chemical Physics Letters 2016;661:36-41. [DOI: 10.1016/j.cplett.2016.08.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Kilany S, Ata L, Gomaa A, Sabry A, Nada A, Tharwa ES, Badra G, Abogabal A, Elwaraky M, Moaz E, Ezzat S, Elsharawy A, Waked I. Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and Cirrhosis. J Hepatocell Carcinoma 2021;8:925-35. [PMID: 34408991 DOI: 10.2147/JHC.S295330] [Reference Citation Analysis]
13 Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One 2017;12:e0172159. [PMID: 28245248 DOI: 10.1371/journal.pone.0172159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
14 Bandiera S, Billie Bian C, Hoshida Y, Baumert TF, Zeisel MB. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol. 2016;20:99-105. [PMID: 27741441 DOI: 10.1016/j.coviro.2016.09.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
15 Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF, Duverlie G, Séron K, Penin F, Dubuisson J. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. J Virol 2014;88:10584-97. [PMID: 24990994 DOI: 10.1128/JVI.01402-14] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
16 Ayad M, Costantine MM. Epidemiology of medications use in pregnancy. Semin Perinatol 2015;39:508-11. [PMID: 26358804 DOI: 10.1053/j.semperi.2015.08.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
17 Ezzikouri S, Jadid FZ, Hamdi S, Wakrim L, Tsukiyama-Kohara K, Benjelloun S. Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus-Associated Type 2 Diabetes: A Mini Review. J Clin Transl Hepatol 2016;4:228-33. [PMID: 27777890 DOI: 10.14218/JCTH.2016.00021] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, Andreone P, Vinci M, Coppola C, Chemello L, Madonia S, Verucchi G, Persico M, Zuin M, Puoti M, Alberti A, Nardone G, Massari M, Montalto G, Foti G, Rumi MG, Quaranta MG, Cicchetti A, Craxì A, Vella S; PITER Collaborating Group. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology 2017;66:1814-25. [PMID: 28741307 DOI: 10.1002/hep.29399] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
19 Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. J Viral Hepat 2021. [PMID: 34661320 DOI: 10.1111/jvh.13625] [Reference Citation Analysis]
20 Rolli FR, Ruggeri M, Kheiraoui F, Drago C, Basile M, Favaretti C, Cicchetti A. Economic evaluation of Zepatier for the management of HCV in the Italian scenario. Eur J Health Econ 2018;19:1365-74. [PMID: 29696459 DOI: 10.1007/s10198-018-0980-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhu SS, Zeng QL, Dong Y, Xu ZQ, Wang LM, Chen DW, Gan Y, Wang FC, Yan JG, Cao LL, Wang P, Han J, Zhang XX, Zhang Z, Zhang HF, Wang FS. Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C. Hepatol Int 2015;9:578-85. [PMID: 26449425 DOI: 10.1007/s12072-015-9671-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Tawar RG, Mailly L, Baumert TF. A new HCV mouse model on the block. Cell Res 2014;24:1153-4. [PMID: 25257465 DOI: 10.1038/cr.2014.126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
23 Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79-S90. [PMID: 25443348 DOI: 10.1016/j.jhep.2014.07.010] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 15.5] [Reference Citation Analysis]
24 Chi X, Niu Y, Cheng M, Liu X, Feng Y, Zheng F, Fan J, Li X, Jin Q, Zhong J, Li YP, Yang W. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Sci Rep 2016;6:25224. [PMID: 27121372 DOI: 10.1038/srep25224] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
25 Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017;15:52. [PMID: 28288626 DOI: 10.1186/s12916-017-0815-7] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 17.4] [Reference Citation Analysis]
26 Lui FH, Moosvi Z, Patel A, Hussain S, Duong A, Duong J, Nguyen DL. Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis. Ann Gastroenterol. 2020;33:293-298. [PMID: 32382233 DOI: 10.20524/aog.2020.0470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
27 Crouchet E, Lefèvre M, Verrier ER, Oudot MA, Baumert TF, Schuster C. Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux. Gut 2017;66:896-907. [PMID: 27609828 DOI: 10.1136/gutjnl-2015-311289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
28 Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:105-114. [PMID: 26157746 DOI: 10.3350/cmh.2015.21.2.105] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 11.4] [Reference Citation Analysis]
29 Yao M, Lu X, Lei Y, Yang J, Zhao H, Qiao Q, Han P, Xu Z, Yin W. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity. PLoS One 2016;11:e0150894. [PMID: 26943641 DOI: 10.1371/journal.pone.0150894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Behera MK, Shukla SK, Dixit VK, Nath P, Abhilash VB, Asati PK, Jain AK. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian J Med Res 2018;148:200-6. [PMID: 30381543 DOI: 10.4103/ijmr.IJMR_1295_15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
31 Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF. Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design. Front Immunol 2018;9:1436. [PMID: 29977246 DOI: 10.3389/fimmu.2018.01436] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
32 Masavuli MG, Wijesundara DK, Underwood A, Christiansen D, Earnest-Silveira L, Bull R, Torresi J, Gowans EJ, Grubor-Bauk B. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice. Front Immunol. 2019;10:1145. [PMID: 31178869 DOI: 10.3389/fimmu.2019.01145] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
33 Jafri W, Kamran M. Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian J Hepatogastroenterol 2019;9:27-33. [PMID: 31988864 DOI: 10.5005/jp-journals-10018-1292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut. 2015;64:1296-1302. [PMID: 25143343 DOI: 10.1136/gutjnl-2014-307862] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
35 Antwi SO, Petrick JL, Campbell PT, Norez DA, Stevens VL, Liao LM, Roberts LR, Patel T, McGlynn KA. One-carbon metabolism-related micronutrients intake and risk for hepatocellular carcinoma: A prospective cohort study. Int J Cancer 2020;147:2075-90. [PMID: 32285447 DOI: 10.1002/ijc.33007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Lafferty L, Wild TC, Rance J, Treloar C. A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons. Harm Reduct J 2018;15:39. [PMID: 30075728 DOI: 10.1186/s12954-018-0246-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Trooskin SB, Poceta J, Towey CM, Yolken A, Rose JS, Luqman NL, Preston TW, Chan PA, Beckwith C, Feller SC, Lee H, Nunn AS. Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. J Gen Intern Med 2015;30:950-7. [PMID: 25680353 DOI: 10.1007/s11606-015-3209-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 7.9] [Reference Citation Analysis]
38 Zucker J, Aaron JG, Feller DJ, Slowikowski J, Evans H, Scherer ML, Yin MT, Gordon P. Development and Validation of an Electronic Medical Record-Based Algorithm to Identify Patient Milestones in the Hepatitis C Virus Care Cascade. Open Forum Infect Dis 2018;5:ofy153. [PMID: 30046641 DOI: 10.1093/ofid/ofy153] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Cholankeril G, Yoo ER, Perumpail RB, Liu A, Sandhu JS, Nair S, Hu M, Ahmed A. Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease. Diseases 2017;5:E20. [PMID: 28954412 DOI: 10.3390/diseases5040020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
40 Röhrs S, Begeman L, Straub BK, Boadella M, Hanke D, Wernike K, Drewes S, Hoffmann B, Keller M, Drexler JF, Drosten C, Höper D, Kuiken T, Ulrich RG, Beer M. The Bank Vole (Clethrionomys glareolus)—Small Animal Model for Hepacivirus Infection. Viruses 2021;13:2421. [DOI: 10.3390/v13122421] [Reference Citation Analysis]
41 Jindai K, Crawford C, Thomas AR. Short-Term Incidence of Sequelae of HCV Infection Among Medicaid Beneficiaries in Oregon. Public Health Rep 2019;134:81-8. [PMID: 30508493 DOI: 10.1177/0033354918813552] [Reference Citation Analysis]
42 Lohmann V. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. Med Microbiol Immunol 2019;208:3-24. [PMID: 30298360 DOI: 10.1007/s00430-018-0566-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
43 Logan M, Law J, Wong JAJ, Hockman D, Landi A, Chen C, Crawford K, Kundu J, Baldwin L, Johnson J, Dahiya A, LaChance G, Marcotrigiano J, Law M, Foung S, Tyrrell L, Houghton M. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. J Virol 2017;91:e01552-16. [PMID: 27795422 DOI: 10.1128/JVI.01552-16] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
44 Majzoub K, Hafirassou ML, Meignin C, Goto A, Marzi S, Fedorova A, Verdier Y, Vinh J, Hoffmann JA, Martin F, Baumert TF, Schuster C, Imler JL. RACK1 controls IRES-mediated translation of viruses. Cell 2014;159:1086-95. [PMID: 25416947 DOI: 10.1016/j.cell.2014.10.041] [Cited by in Crossref: 113] [Cited by in F6Publishing: 101] [Article Influence: 16.1] [Reference Citation Analysis]
45 Zhao F, Zhao T, Deng L, Lv D, Zhang X, Pan X, Xu J, Long G. Visualizing the Essential Role of Complete Virion Assembly Machinery in Efficient Hepatitis C Virus Cell-to-Cell Transmission by a Viral Infection-Activated Split-Intein-Mediated Reporter System. J Virol 2017;91:e01720-16. [PMID: 27852847 DOI: 10.1128/JVI.01720-16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
46 Sudhindar PD, Wainwright D, Saha S, Howarth R, McCain M, Bury Y, Saha SS, McPherson S, Reeves H, Patel AH, Faulkner GJ, Lunec J, Shukla R. HCV Activates Somatic L1 Retrotransposition-A Potential Hepatocarcinogenesis Pathway. Cancers (Basel) 2021;13:5079. [PMID: 34680227 DOI: 10.3390/cancers13205079] [Reference Citation Analysis]
47 Kitab B, Satoh M, Ohmori Y, Munakata T, Sudoh M, Kohara M, Tsukiyama-Kohara K. Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation. J Biol Chem. 2019;294:5759-5773. [PMID: 30755480 DOI: 10.1074/jbc.ra118.004397] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
48 Zeisel MB, Crouchet E, Baumert TF, Schuster C. Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses 2015;7:5659-85. [PMID: 26540069 DOI: 10.3390/v7112898] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
49 Soto-Gutierrez A, Gough A, Vernetti LA, Taylor DL, Monga SP. Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems. Exp Biol Med (Maywood). 2017;242:1605-1616. [PMID: 28467181 DOI: 10.1177/1535370217707731] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
50 Bartlett JG. Why infectious diseases. Clin Infect Dis 2014;59 Suppl 2:S85-92. [PMID: 25151484 DOI: 10.1093/cid/ciu441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
51 Douglas MW, Tay ESE, Wang DS, Ong ATL, Wilson C, Phu A, Kok J, Dwyer DE, Bull RA, Lloyd AR, Applegate TL, Dore GJ, Howe AY, Harrigan R, George J. Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatol Commun 2020;4:904-15. [PMID: 32490325 DOI: 10.1002/hep4.1496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Fauvelle C, Lambotin M, Heydmann L, Prakash E, Bhaskaran S, Vishwaraman M, Baumert TF, Moog C. A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry. Hepatol Int 2017;11:440-5. [PMID: 28698985 DOI: 10.1007/s12072-017-9809-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
53 Li YC, Zhang MQ, Zhang JP. Opposite Effects of Two Human ATG10 Isoforms on Replication of a HCV Sub-genomic Replicon Are Mediated via Regulating Autophagy Flux in Zebrafish. Front Cell Infect Microbiol 2018;8:109. [PMID: 29670865 DOI: 10.3389/fcimb.2018.00109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Haqshenas G, Wu J, Simpson KJ, Daly RJ, Netter HJ, Baumert TF, Doerig C. Signalome-wide assessment of host cell response to hepatitis C virus. Nat Commun 2017;8:15158. [PMID: 28480889 DOI: 10.1038/ncomms15158] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
55 Douam F, Fusil F, Enguehard M, Dib L, Nadalin F, Schwaller L, Hrebikova G, Mancip J, Mailly L, Montserret R, Ding Q, Maisse C, Carlot E, Xu K, Verhoeyen E, Baumert TF, Ploss A, Carbone A, Cosset FL, Lavillette D. A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism. PLoS Pathog 2018;14:e1006908. [PMID: 29505618 DOI: 10.1371/journal.ppat.1006908] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
56 Ke R, Loverdo C, Qi H, Sun R, Lloyd-Smith JO. Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. PLoS Comput Biol 2015;11:e1004040. [PMID: 26125950 DOI: 10.1371/journal.pcbi.1004040] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
57 Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22:141-150. [PMID: 30455585 DOI: 10.5114/wo.2018.78941] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 15.8] [Reference Citation Analysis]
58 Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol 2015; 7(17): 2100-2109 [PMID: 26301052 DOI: 10.4254/wjh.v7.i17.2100] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
59 Ezzat WM, Amr KS. Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention. World J Hepatol 2016; 8(30): 1251-1261 [PMID: 27843535 DOI: 10.4254/wjh.v8.i30.1251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
60 Goossens N, Hoshida Y. Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) 2015;5:132-5. [PMID: 26213619 DOI: 10.1002/cld.483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
61 Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape. Gut 2018;67:736-45. [PMID: 28360099 DOI: 10.1136/gutjnl-2016-312577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
62 Karageorgopoulos DE, Allen J, Bhagani S. Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a “special population”? World J Hepatol 2015; 7(15): 1936-1952 [PMID: 26244068 DOI: 10.4254/wjh.v7.i15.1936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
63 Kumar A, Pandey R, Yadav IS, Bharadwaj M. Structural and Epitope Analysis (T- and B-Cell Epitopes) of Hepatitis C Virus (HCV) Glycoproteins: An in silico Approach. J Clin Exp Hepatol 2018;8:352-61. [PMID: 30568344 DOI: 10.1016/j.jceh.2017.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
64 Shirasaki T, Honda M, Yamashita T, Nio K, Shimakami T, Shimizu R, Nakasyo S, Murai K, Shirasaki N, Okada H, Sakai Y, Sato T, Suzuki T, Yoshioka K, Kaneko S. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication. Sci Rep 2018;8:13143. [PMID: 30177680 DOI: 10.1038/s41598-018-31421-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
65 Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y; Precision Liver Cancer Prevention Consortium. Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell 2016;30:879-90. [PMID: 27960085 DOI: 10.1016/j.ccell.2016.11.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 100] [Article Influence: 20.2] [Reference Citation Analysis]
66 Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol 2018;11:1756284818759483. [PMID: 29619090 DOI: 10.1177/1756284818759483] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
67 Rasche A, Sander AL, Corman VM, Drexler JF. Evolutionary biology of human hepatitis viruses. J Hepatol 2019;70:501-20. [PMID: 30472320 DOI: 10.1016/j.jhep.2018.11.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
68 Jalan R. 'Hepatology' on the move. Liver Int 2014;34:820-1. [PMID: 24935765 DOI: 10.1111/liv.12602] [Reference Citation Analysis]
69 Sauerbruch T, Trebicka J. Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep. 2014;6:95. [PMID: 25374673 DOI: 10.12703/P6-95] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
70 Paciello R, Urbanowicz RA, Riccio G, Sasso E, McClure CP, Zambrano N, Ball JK, Cortese R, Nicosia A, De Lorenzo C. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. J Gen Virol 2016;97:82-94. [PMID: 26519290 DOI: 10.1099/jgv.0.000330] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
71 Hughes HY, Henderson DK. Postexposure prophylaxis after hepatitis C occupational exposure in the interferon-free era. Curr Opin Infect Dis 2016;29:373-80. [PMID: 27306563 DOI: 10.1097/QCO.0000000000000281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
72 Antwi SO, Van Houten HK, Sangaralingham LR, Patel T. Risk of De Novo Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C. Cancer Prev Res (Phila) 2019;12:891-902. [PMID: 31451519 DOI: 10.1158/1940-6207.CAPR-19-0162] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Baumert TF, Hoshida Y. Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma. Viruses 2019;11:E441. [PMID: 31096600 DOI: 10.3390/v11050441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
74 Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut. 2018;67:953-962. [PMID: 28159835 DOI: 10.1136/gutjnl-2016-312270] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
75 Felmlee DJ, Schuster C, Baumert TF. New tool for the study of hepatitis C virus genotype 3 and its associated liver disease biology. Hepatology 2014;60:1806-8. [PMID: 25049145 DOI: 10.1002/hep.27326] [Reference Citation Analysis]
76 Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol 2015;2:371-9. [PMID: 26617981 DOI: 10.2217/hep.15.26] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
77 Dhiman RK. Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability? J Clin Exp Hepatol 2014;4:85-6. [PMID: 25755543 DOI: 10.1016/j.jceh.2014.06.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
78 Colpitts CC, Baumert TF. Viral hepatitis: A new HCV cell culture model for the next clinical challenges. Nat Rev Gastroenterol Hepatol 2015;12:611-3. [PMID: 26441247 DOI: 10.1038/nrgastro.2015.170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Fénéant L, Potel J, François C, Sané F, Douam F, Belouzard S, Calland N, Vausselin T, Rouillé Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L. New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. J Virol 2015;89:8346-64. [PMID: 26041282 DOI: 10.1128/JVI.00192-15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
80 Vausselin T, Séron K, Lavie M, Mesalam AA, Lemasson M, Belouzard S, Fénéant L, Danneels A, Rouillé Y, Cocquerel L, Foquet L, Rosenberg AR, Wychowski C, Meuleman P, Melnyk P, Dubuisson J. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. J Virol 2016;90:8422-34. [PMID: 27412600 DOI: 10.1128/JVI.00404-16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
81 Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB. Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis. J Virol. 2016;90:6387-6400. [PMID: 27147737 DOI: 10.1128/jvi.00619-16] [Cited by in Crossref: 64] [Cited by in F6Publishing: 40] [Article Influence: 10.7] [Reference Citation Analysis]
82 Holmström F, Chen M, Balasiddaiah A, Sällberg M, Ahlén G, Frelin L. Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses. Sci Rep 2016;6:24991. [PMID: 27141891 DOI: 10.1038/srep24991] [Reference Citation Analysis]
83 Fuerst TR, Pierce BG, Keck ZY, Foung SKH. Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus. Front Microbiol 2017;8:2692. [PMID: 29379486 DOI: 10.3389/fmicb.2017.02692] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
84 Shiani A, Narayanan S, Pena L, Friedman M. The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer. Cancer Control 2017;24:1073274817729240. [PMID: 28975833 DOI: 10.1177/1073274817729240] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
85 Funaki M, Kitabayashi J, Shimakami T, Nagata N, Sakai Y, Takegoshi K, Okada H, Murai K, Shirasaki T, Oyama T, Yamashita T, Ota T, Takuwa Y, Honda M, Kaneko S. Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Sci Rep 2017;7:16978. [PMID: 29208982 DOI: 10.1038/s41598-017-17285-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
86 Yunihastuti E, Amelia F, Hapsari AI, Wicaksana B, Natali V, Widhani A, Sulaiman AS, Karjadi TH. Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus. Health Qual Life Outcomes 2021;19:154. [PMID: 34039353 DOI: 10.1186/s12955-021-01777-x] [Reference Citation Analysis]
87 Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF. Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection. Hepatology 2019;70:1506-20. [PMID: 31062385 DOI: 10.1002/hep.30699] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
88 Munyemana JB, Mukanoheli E, Nsabimana T, Niringiyumukiza JD. HCV Seroprevalence among HIV Patients and Associated Comorbidities at One Primary Health Facility in Rwanda. Am J Trop Med Hyg 2021:tpmd200500. [PMID: 33720846 DOI: 10.4269/ajtmh.20-0500] [Reference Citation Analysis]
89 Qian L, Wang N, Tian H, Jin H, Zhao H, Niu C, He H, Ge T, Han W, Hu J, Li D, Han F, Xu J, Ding X, Chen J, Li W, Cui J. Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients. J Immunol Res. 2016;2016:6837241. [PMID: 27069936 DOI: 10.1155/2016/6837241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
90 Abdel Wahab M, Shehta A, Ibrahim EM, Eldesoky RT, Sultan AA, Zalata KR, Fathy O, Elshoubary M, Salah T, Yassen AM, Elmorshedi M, Monier A, Farouk A, Shiha U. Adrenalectomy for solitary recurrent hepatocellular carcinoma five years after living donor liver transplantation: A case report. Int J Surg Case Rep 2019;54:23-7. [PMID: 30513494 DOI: 10.1016/j.ijscr.2018.11.062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Spradling PR, Xing J, Rupp LB, Moorman AC, Gordon SC, Lu M, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015. J Clin Gastroenterol 2018;52:641-7. [PMID: 28590325 DOI: 10.1097/MCG.0000000000000857] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
92 Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection. Viruses. 2018;10. [PMID: 30274202 DOI: 10.3390/v10100531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
93 Abushouk AI, El-Husseny MWA, Magdy M, Ismail A, Attia A, Ahmed H, Pallanti R, Negida A. Evidence for association between hepatitis C virus and Parkinson's disease. Neurol Sci 2017;38:1913-20. [PMID: 28780707 DOI: 10.1007/s10072-017-3077-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
94 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
95 Ogishi M, Yotsuyanagi H, Tsutsumi T, Gatanaga H, Ode H, Sugiura W, Moriya K, Oka S, Kimura S, Koike K. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. PLoS One. 2015;10:e0119145. [PMID: 25748426 DOI: 10.1371/journal.pone.0119145] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
96 Crouchet E, Baumert TF, Schuster C. Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact. Expert Rev Proteomics 2017;14:593-606. [PMID: 28625086 DOI: 10.1080/14789450.2017.1344102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
97 Sasso E, Paciello R, D'Auria F, Riccio G, Froechlich G, Cortese R, Nicosia A, De Lorenzo C, Zambrano N. One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1. Biomed Res Int 2015;2015:703213. [PMID: 26649313 DOI: 10.1155/2015/703213] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]